U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C41H64F2O7
Molecular Weight 706.9395
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Rofleponide 21-palmitate

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(O[C@H](CCC)O2)C(=O)COC(=O)CCCCCCCCCCCCCCC

InChI

InChIKey=IRCYEVZQEUIZIW-NEESCNQASA-N
InChI=1S/C41H64F2O7/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-20-36(47)48-27-34(46)41-35(49-37(50-41)19-6-2)25-29-30-24-32(42)31-23-28(44)21-22-38(31,3)40(30,43)33(45)26-39(29,41)4/h23,29-30,32-33,35,37,45H,5-22,24-27H2,1-4H3/t29-,30-,32-,33-,35+,37+,38-,39-,40-,41+/m0/s1

HIDE SMILES / InChI

Molecular Formula C41H64F2O7
Molecular Weight 706.9395
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Rofleponide is a third generation synthetic glucocorticosteroid. This compound has high affinity for the rat thymus glucocorticoid receptor and showed a very high biotransformation rate in the human liver. Rofleponide was being investigated for its anti-inflammatory, immunosuppressive and anti-anaphylactic activity. It was evaluated in phase II clinical trials for its safety and efficacy in allergic rhinitis and asthma, and in a preclinical study for use in inflammatory bowel disease, but development of this drug was discontinued. Rofleponide was never marketed.

Approval Year

Substance Class Chemical
Record UNII
8KB3J5M6UG
Record Status Validated (UNII)
Record Version